|
AU2002353180A1
|
|
Use of ugt inhibitors to increase bioavailability
|
|
AU6107500A
|
|
Improvement of bioavailability with vitamin c fatty acid esters
|
|
AU3392900A
|
|
Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
|
|
EP1056455A1
|
|
Epimorphian compound and its use
|
|
US5962522A
|
|
Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
|
|
WO9640192A1
|
|
Use of essential oils to increase bioavailability of oral pharmaceutical compounds
|
|
US5716928A
|
|
Use of essential oils to increase bioavailability of oral pharmaceutical compounds
|
|
US5665386A
|
|
Use of essential oils to increase bioavailability of oral pharmaceutical compounds
|
